PDCD1 and glioblastoma: (226) evaluated the anti-PD-1 checkpoint inhibitor nivolumab intravenously in patients with recurrent GBM in a phase I trial, both as monotherapy or in combination with CTLA-4 blocking mAb ipilimumab at different dose levels.